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Abstract
Background: Guidelines for frequency of Type 2 diabetes mellitus (DM) screening remain unclear, with proposed
screening intervals typically based on expert opinion. This study aims to demonstrate that HbA1c screening
intervals may differ substantially when considering individual risk for diabetes.
Methods: This was a multi-institutional retrospective open cohort study. Data were collected between April 1999 to
March 2014 from one urban and one rural cohort in Japan. After categorization by age, we stratified individuals
based on cardiovascular disease risk (Framingham 10-year cardiovascular risk score) and body mass index (BMI). We
adapted a signal-to-noise method for distinguishing true HbA1c change from measurement error by constructing a
linear random effect model to calculate signal and noise of HbA1c. Screening interval for HbA1c was defined as
informative when the signal-to-noise ratio exceeded 1.
Results: Among 96,456 healthy adults, 46,284 (48.0%) were male; age (range) and mean HbA1c (SD) were 48
(30–74) years old and 5.4 (0.4)%, respectively. As risk increased among those 30–44 years old, HbA1c
screening intervals for detecting Type 2 DM consistently decreased: from 10.5 (BMI <18.5) to 2.4 (BMI > 30)
years, and from 8.0 (Framingham Risk Score <10%) to 2.0 (Framingham Risk Score ≥20%) years. This trend
was consistent in other age and risk groups as well; among obese 30–44 year olds, we found substantially
shorter intervals compared to other groups.
Conclusion: HbA1c screening intervals for identification of DM vary substantially by risk factors. Risk
stratification should be applied when deciding an optimal HbA1c screening interval in the general population
to minimize overdiagnosis and overtreatment.
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Background
Type 2 diabetes mellitus (DM) affects approximately 7.2
million adults in Japan, with a worldwide prevalence of
387 million in 2013 [1]. Its growing prevalence and
strong association with a number of later complications,
including cardiovascular events, has prompted the regu-
lar screening of healthy adults. However, screening
guidelines for frequency of HbA1c testing remain
unclear, and proposed screening intervals have been typ-
ically based on expert opinion.
In Japan, for example, a large majority of the popula-
tion, including virtually all employed adults, receive free
annual health checkups mandated by the 1972 Industrial
Safety and Health Act, which typically include annual
DM screening. In the United States, the American Dia-
betes Association recommends that screening for Type 2
DM in adults occur roughly every 3 years, though this is
level IV evidence (expert opinion) [2–4]. In the UK,
NICE guidelines recommend that general practitioners
first utilize risk assessment tools such as the Cambridge
diabetes risk score [5] or Leicester practice score [6]
before measuring HbA1c, measuring HbA1c only if
patients are found to be at high risk with subsequent re-
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screening every 3 years [7, 8]. Anecdotal data suggest,
however, that clinicians provide overly frequent screen-
ing, often annually, for a large number of apparently
healthy patients [9], despite existing data suggesting that
this is not necessary [7, 10]. This may be especially prob-
lematic given that previous analyses of the characteris-
tics of the HbA1c assay have demonstrated that the test
possesses significant short-term variability, and that too-
frequent testing may lead to diagnostic confusion [11].
The risk of developing Type 2 DM differs with age,
obesity, and lack of physical activity [12]. A CDC report
estimates an incidence of new onset diabetes of 7.8 per
1000 adults; however, this varies substantially from 3.6
cases for those under 44 years old to 12.0 for those from
those 45–64 years old [13]. Similarly, a previous study
reported that, in comparison with normal BMI, those
with a BMI of 30–39.9 kg/m2 had an OR of 3.66 for
being diagnosed with DM [14]. However, none of these
previous studies have proposed different intervals for
testing based on risk stratification [15, 16], despite
suggesting that screening protocols tailored to specific
at-risk patient populations are preferable.
In order to demonstrate that screening intervals may
be substantially different when considering risk stratifi-
cation, our study uses two clinically feasible risk stratifi-
cation strategies, Framingham (10-year cardiovascular)
risk [17] and BMI, to better define screening intervals
while accounting for true change of HbA1c versus meas-
urement error. We chose BMI as a basis of stratification
as previous reports show different incidence rate of DM
based on BMI classification [14]; we chose Framingham
Risk Score as for stratification to reflect that DM is
considered a clinical cardiovascular events -risk equiva-
lent [18, 19]. We hypothesize that informative screening
intervals for HbA1c will be shorter as individual risk
increases.
Methods
This was a retrospective open cohort study, combining an
urban and rural population in Japan. The urban cohort was
collected from St. Luke’s International Hospital Center for
Preventive Medicine (Tokyo, Japan) between January 2005
and December 2014. Approximately 80% of participants
were either employees or dependents of various companies
and local government organizations in metropolitan Tokyo,
health screening costs for whom were paid by the em-
ployer. The remaining 20% of participants were residents of
Tokyo, independently registering and paying for the pro-
gram. The rural cohort was collected from the Yamanashi
Koseiren Health Care Center (Yamanashi, Japan) between
April 1999 and March 2009 as part of a private health
check-up service. Data in both cohorts included individuals
presenting for health screening at least twice, with no previ-
ous history of Type 2 DM or cardiovascular events at first
visit, and with complete data on risk equation covariates for
Framingham Risk Score. Consistent with previous studies,
patients were classified into 3 age groups (30–44, 45–59,
and 60–74 years) [3, 15]. Clinically relevant demographic,
historical, and lifestyle parameters were collected via a stan-
dardized questionnaire provided to all patients and
reviewed by a trained healthcare provider. In addition to
collecting physiometric data at the time of visit, HbA1c was
collected as part of the standard serum testing panel from
all patients at each visit. Each respective model was gener-
ated based on one of two risk stratification methods: (I)
BMI classification (underweight, BMI <18.5; normal weight,
BMI 18.6–24.9; overweight, BMI 25–29.9; and obese, BMI
≥30 [20, 21]); or (II) Framingham Risk Score for 10-year
cardiovascular risk (low risk, <10%; moderate risk, 10% ≤
score < 20%; and high risk, ≥20%) [22, 23]. BMI and
Framingham Risk Score parameters were collected during
the routine health check up at the same time and in
the same facility in which HbA1c was measured; the
Framingham Risk Score has been previously validated
in the Japanese population [24].
Calculating signal and noise for laboratory testing
To distinguish true change in HbA1c progression, we
adapted a statistical method for distinguishing the proper-
ties of tests from the variability of measurements; the meth-
odology has been described in detail elsewhere [25, 26].
Briefly, linear random effect models with random intercept
and random slope, adjusted for gender, age and BMI at first
measurement of HbA1c as continuous value, were used to
derive parameters describing HbA1c progression. These pa-
rameters include the long-term variability among individ-
uals in the population (“signal”), as well as the short-term
within-person variability (“noise”) (Appendix 5). In the ran-
dom effect model, noise was obtained by calculating the
variance of residuals between observed and model-
generated HbA1c values. Signal was obtained by calculat-
ing, at each time point, the variance of random slope of
each participant multiplied by each time point squared.
Equations with detailed footnotes are shown in Table 1. We
use the signal-to-noise ratio (SNR) as a quantitative marker
to distinguish individuals with true HbA1c change from
those with apparent change due to noise. Based on previous
reports, we defined the minimal informative screening
interval as the time at which the signal to noise ratio ex-
ceeds 1 [26, 27]. We calculated confidence intervals for
these ratios through non-parametric bootstrapping (15,000
times).
All models were fitted in Stata software version 12.1
(StataCorp LP, College Station, Texas, USA).
Ethics, consent and permission
When patients presented to both medical facilities, they
were provided with a document explaining that their
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anonymous data may be used for research purposes.
While written informed consent was not provided, both
institutions provided opt-out policy information in paper
form and all patients had the opportunity to refuse use of
their information from the electronic medical record.
Ethical approval was obtained from two committees: the
Research Ethics Committee of St. Luke’s International
Hospital (approval code: 15-R044) as well as the Research
Ethics Committee of University of Yamanashi (approval
code: 1418).
Results
Of the 149,191 adults in both cohorts, 96,456 healthy
adults with an average age (SD) of 48.0 (10.6) years, com-
prising 46,284 (48.0%) males, were eligible for inclusion in
this study. Exclusions are shown in the flow chart in Fig. 1.
There were no clinically relevant differences between
urban and rural cohorts in terms of HbA1c and BMI;
mean HbA1c in the urban and rural cohorts was 5.5%
(0.3) and 5.3% (0.4), respectively. Mean BMI was 22.3 (3.2)
kg/m2 in the urban cohort and 22.7 (3.0) kg/m2 in the
rural cohort. Mean (SD) age of the rural cohort was
roughly 5 years older than that of the urban cohort at 51.2
(10.2) versus 46.5 (10.4) years, respectively. Mean (SD)
Framingham Risk Score was slightly higher in rural than
urban cohort, at 9.0% (0.08) and 6.0% (0.07), respectively.
The proportion of current smokers in the rural cohort
was twice that of the urban cohort. We merged the two
cohorts into a single population for subsequent analyses
to increase the generalizability of this study. Table 2 shows
baseline characteristics for pooled data by age group.
The majority of the cohort were of normal weight
(BMI 18–24.9 kg/m2): 71.0% for ages 30–44, 72.4%
for ages 45–59, and 74.0% for those 60–74 years old.
Patients were similarly concentrated in the low risk
(0–10%) group of Framingham Risk Score: 97.7% for
those 30–44 years old, 73.3% for 45–59 years old,
and 36.7% for those 60–74 years old.
Screening and BMI
Figure 2 show the time interval at which the signal
exceeded noise for each BMI stratification by age group.
For those aged 30–59 years old, the DM screening inter-
val for HbA1c decreased as BMI increased. In under-
weight and normal weight individuals 60–74 years old,
screening intervals were similar. In all age groups,
underweight and normal weight individuals appeared to
warrant less HbA1c screening compared to those in the
heavier group. Obesity in the 30–44 year old group was
associated with substantially shorter intervals compared
to other age groups.
Screening and cardiovascular risk
Figure 3 shows the time at which the signal exceeded
noise, stratified by Framingham Risk Score and age.
For all age groups, DM screening intervals decreased
as Framingham Risk Score increased. Similar to BMI
stratification, the highest Framingham risk group in
those 30–44 years old demonstrated a much shorter
interval than those in other age groups. These results
were consistent even after analyzing data in each
cohort independently (Appendix 1, 2, 3 and 4). We
found that informative intervals were, predictably,
Table 1 Equations of applied models
Random effect model: Yij = Uij + εij
Observed HbA1c: Yij
Noise: εij
Signal: Uij = αij + βij * T
αi ~ N(α,σa2) , βi ~ N(β,σb2), with covariance (αi ,βi) = σab
εij ~ N(0,σw2)
Y is the observed HbA1c, equal to the true change and the measurement
error, ε. U is the true change in HbA1c for individual for individual i at time j, α
is the baseline HbA1c, β is the annual progression rate. T represents time since
first measurement. The notation ~ N(x,y) refers to a normal distribution with a
mean x and a variance y, so the other main assumption of the model is
normality in the distributions of α, β and ε. From this model, the short-term
variability is equal to the variance of the measurement error (σ2w) whereas
the long-term variability is equal to the variance of the annual progression
rate (σ2β)
Fig. 1 Study flow
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Table 2 Baseline characteristics of study participants
Age between 30 and 44
Total St. Luke’s Yamanashi
Numbers N = 41,400 N = 32,820 N = 8,580
Age 38.0 ± 3.9 37.8 ± 4.0 38.4 ± 3.8
Gender, male 19,572 (47.3%) 15,085 (46.0%) 4,487 (52.%)
Stratification
10-year cardiovascular risk Framingham Risk Score Lowest risk (0–10%) 40,434 (97.7%) 32,247 (98.3%) 8,187 (95.4%)
Intermediate risk (10–20%) 859 (2.1%) 481 (1.5%) 378 (4.4%)
High risk (over20%) 107 (0.3%) 92 (0.3%) 15 (0.2%)
BMI category Underweight (bmi <18 · 5) 4,853 (11.7%) 3,950 (12.0%) 903 (10.5%)
Normal (18 · 5 < =bmi < 25) 29,382 (71.0%) 23,365 (71.2%) 6,017 (70.1%)
Overweight (25 < =bmi < 30) 6,199 (15.0%) 4,762 (14.5%) 1,437 (16.8%)
Obese (30 < =bmi) 966 (2.3%) 743 (2.3%) 223 (2.6%)
Baseline HbA1c 5.3 ± 0.3 5.4 ± 0.3 5.2 ± 0.3
Baseline BMI 22.1 ± 3.3 22.0 ± 3.3 22.3 ± 3.4
Current smoker 8,562 (20.7%) 5,733 (17.5%) 2,829 (33.0%)
Age between 45 and 59
Total St. Luke’s Yamanashi
Numbers N = 38,609 N = 24,539 N = 14,070
Age 51.6 ± 4.3 51.4 ± 4.3 51.9 ± 4.2
Gender, male 18,606 (48.2%) 12,162 (49.6%) 6,444 (45.8%)
Stratification
10-year cardiovascular risk Framingham Risk Score Lowest risk (0–10%) 28,298 (73.3%) 18,673 (76.1%) 9,625 (68.4%)
Intermediate risk (10–20%) 8,293 (21.5%) 4,826 (19.7%) 3,467 (24.6%)
High risk (over20%) 2,018 (5.2%) 1,040 (4.2%) 978 (7.0%)
BMI category Underweight (bmi <18 · 5) 2,437 (6.3%) 1748 (7.1%) 689 (4.9%)
Normal (18 · 5 < =bmi < 25) 27,960 (72.4%) 17,472 (71.2%) 10,488 (74.5%)
Overweight (25 < =bmi < 30) 7,440 (19.3%) 4,767 (19.4%) 2,673 (19.0%)
Obese (30 < =bmi) 772 (2.0%) 552 (2.2%) 220 (1.6%)
Baseline HbA1c 5.5 ± 0.4 5.5 ± 0.3 5.3 ± 0.4
Baseline BMI 22.7 ± 3.1 22.7 ± 3.2 22.8 ± 2.9
Current smoker 7,746 (20.1%) 4,225 (17.2%) 3,521 (25.0%)
Age between 60 and 74
Total St. Luke’s Yamanashi
N = 16,447 N = 8,801 N = 7,646
Age 64.6 ± 3.8 65.0 ± 3.9 64.2 ± 3.7
Gender, male 8,106 (49.3%) 4,513 (51.3%) 3,593 (47.0%)
Stratification
10-year cardiovascular risk Framingham Risk Score Lowest risk (0–10%) 6,041 (36.7%) 3,341 (37.9%) 2,700 (35.3%)
Intermediate risk (10–20%) 6,276 (38.2%) 3,356 (38.1%) 2,920 (38.2%)
High risk (over20%) 4,130 (25.1%) 2,104 (23.9%) 2,026 (26.5%)
BMI category Underweight (bmi <18 · 5) 933 (5.7%) 573 (6.5%) 360 (4.7%)
Normal (18 · 5 < =bmi < 25) 12,164 (74.0%) 6,533 (74.2%) 5,631 (73.4%)
Overweight (25 < =bmi < 30) 3,164 (19.2%) 1,606 (18.2%) 1,558 (20.4%)
Obese (30 < =bmi) 186 (1.1%) 89 (1.0%) 97 (1.3%)
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shorter in the high DM risk group compared to low
risk group (Appendix 6) [28].
Discussion
Meaningful screening intervals varied substantially by
BMI, ranging from as long as 10.5 (8.9–12.9) years to as
short as 2.4 (1.6–4.2) years. When Framingham cardio-
vascular risk was used for stratification, monitoring in-
tervals were similarly varied, from 8.0 (7.0–9.3) to 2.0
(1.4–4.0) years. Regardless of the stratification method
employed, analysis of higher risk groups consistently re-
sulted in shorter screening intervals compared to those
at lower risk. While existing guidelines [7, 10] do men-
tion screening intervals, these have been typically based
on a combination of previous studies [15, 16] and expert
opinion, none of which have fully considered risk as a
criteria for screening. An evidence-based optimal screen-
ing interval has not yet been fully explored; our data
suggest that consideration of at least some baseline risk
characteristics is warranted. A 3–5 year monitoring
interval suggested by Kahn et al., while providing good
evidence for cost-effectiveness, does not apply to those
over 45 years old and, more importantly, may not ad-
equately account for varying baseline risk in the adult
population [15]. Further highlighting the possibility that
screening unselected populations for DM may not be
efficacious, Simmons et al. reported finding no associ-
ation between screening and reduction in all-cause,
cardiovascular, or diabetes-related mortality within
10 years [29, 30], a conclusion that was corroborated in
a recent systematic review by the Agency for Health-
care Research and Quality [31]. Our findings suggest
that low risk individuals with a long screening interval,
such as the well elderly, may not warrant screening.
Despite a growing body of evidence that population-
level DM screening may not be useful, we anticipate that
it will remain unpalatable from a societal perspective to
do away with screening entirely, especially in light of
Table 2 Baseline characteristics of study participants (Continued)
Baseline HbA1c 5.6 ± 0.4 5.6 ± 0.3 5.4 ± 0.4
Baseline BMI 22.8 ± 2.8 22.6 ± 2.9 23.0 ± 2.8
Current smoker 1,995 (12.1%) 855 (9.7%) 1,140 (14.9%)
Fig. 2 DM screening intervals for HbA1c screening test by BMI stratification (years). (−) indicates 95% CI of screening interval for HbA1c screening test
calculated by non-parametric 15000 times bootstrapping simulations
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recent reports of the alarmingly high prevalence of DM
and its risk factors, including obesity [32]. As demon-
strated by the substantial heterogeneity of SNR between
risk groups, our data suggest that optimal screening, ra-
ther than following an all-or-nothing approach, should
be tailored to match broad risk profiles, which can be
easily assessed at clinic visits, to improve screening ac-
curacy. Based on actual physician practice, the previ-
ously reported intervals of approximately 3–5 years may
represent reasonable minimal thresholds of re-screening;
however, they appear to be inadequate representations of
re-screening ceilings, which may be substantially longer
in low-risk patients. Future studies should address cost-
effectiveness after considering risk stratification in the
assessment of screening intervals.
This study has some limitations. We relied on self-
reports for some clinical criteria, such as use of DM medi-
cation, DM and cardiovascular event history, as well as
current smoking status for calculating Framingham Risk
Scores. Differences in data collection technique may have
existed between the two cohorts: participants in the urban
cohort received a personalized interview by a trained pre-
ventive health nurse, in order to maximize accuracy of
data, while there was no nurse interview system in the
rural cohort. Despite this, clinically relevant differences
were not seen between the two cohorts. Second, this was
a multi-institutional open cohort study of data collected
from urban and rural Japan. Generalizability to other
countries warrants further exploration. Finally, under
current Japanese occupational health law, contents of
health exams may differ based on employee age; those
under 39 or over 75 years old are not required to have
blood tests, thus raising the possibility of selection bias via
missing data, especially for those 30–39 years old. How-
ever, most companies choose to include screening blood
tests for all employees; in the urban cohort, only 0.03% of
participants failed to have a blood test panel.
Conclusion
When stratifying by risk for DM development, HbA1c
screening intervals varied substantially. Taking into
account differences of true HbA1c change, to avoid
overdiagnosis and overtreatment, risk stratification
should be applied when deciding an optimal HbA1c
screening interval in a specific population. Annual
screening appears to be unwarranted in any risk
group, while those at low risk may not warrant re-
screening for a decade or longer.
Fig. 3 DM screening intervals for Hba1c screening test by Framingham Risk Score stratification (years). (−) indicates 95% CI of screening interval
for HbA1c screening test calculated by non-parametric 15,000 times bootstrapping simulations
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Appendix 1
Appendix 2
Fig. 5 DM screening intervals for HbA1c screening test in the rural cohort by BMI stratification. Description of data: Figure as indicated in title
Fig. 4 DM screening intervals for HbA1c screening test in the urban cohort by BMI stratification. Description of data: Figure as indicated in title
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Appendix 3
Appendix 4
Fig. 6 DM screening intervals for HbA1c screening test in the urban cohort by Framingham Risk Score stratification. Description of data: Figure as
indicated in title
Fig. 7 DM screening intervals for HbA1c screening test in the rural cohort by Framingham Risk Score stratification. Description of data: Figure as
indicated in title




BMI: Body mass index; DM: Type 2 diabetes mellitus; HbA1c: Hemoglobin
A1c; OR: Odds ratio; SD: Standard deviation; SNR: Signal to noise ratio
Acknowledgements
The authors would like to acknowledge the many valuable suggestions
made by professor Kohta Suzuki at Department of Health and Psychosocial
Medicine at Aichi Medical University School of Medicine as well as
researchers at Division of Social Medicine, Department of Health Science,
and Basic Science for Clinical Medicine, Division of Medicine, Graduate
School Department of Interdisciplinary Research, University of Yamanashi.
Funding
This work was supported by The Ministry of Education, Culture, Sports,
Science and Technology (MEXT), Grant-in-Aid for Young Scientists. Grant
Number 26860429.
Availability of data and material
Not applicable.
Authors’ contributions
SO, EM, GD, OT, RP, HY, ZY designed the study. SO, OT, TF, HY, ZY obtained
data. SO, EM, HY analysed data. SO, GD, RP, EM interpreted data. OT, GD, HY,
ZY, TF provided clinical advice. SO, GD wrote the first draft. All authors
revised the manuscript and approved the final version prior to the
submission.
Competing interests
The authors declare that they have no competing interests.
Grant agency did not involve in data collection, analysis, or interpretation;
trial design; patient recruitment; or any aspect pertinent to the study.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Ethical approval was obtained from two committees; the Research Ethics
Committee of St. Luke’s International Hospital, Tokyo, Japan (approval code:
15-R044) as well as the Research Ethics Committee of University of Yamana-
shi, Yamanashi, Japan (approval code: 1418).
Author details
1Center for Clinical Epidemiology, St. Luke’s International University, 10-1
Akashi-cho, Chuo, Tokyo 104-0044, Japan. 2Department of General Internal
Medicine, St. Luke’s International Hospital, 9-1 Akashi-cho, Tokyo 104-8560,
Japan. 3Department of Internal Medicine, University of Hawaii, Honolulu,
Hawaii, USA. 4Nuffield Department of Primary Care Health Sciences,
University of Oxford, Oxford, UK. 5Department of Health Science, Basic
Science for Clinical Medicine, Division of Medicine, Graduate School
Department of Interdisciplinary Research, University of Yamanashi, Kofu,
Japan.
Received: 17 May 2016 Accepted: 18 October 2016
References
1. International Diabetes Federation. IDF Diabetes, 7 ed. Brussels, Belgium:
International Diabetes Federation, 2015. http://www.diabetesatlas.org.
2. American Diabetes Association. Standards of medical care in diabetes-2014.
Diabetes Care. 2014;37 Suppl 1:S14–80.
3. Johnson SL, Tabaei BP, Herman WH. The efficacy and cost of alternative
strategies for systematic screening for type 2 diabetes in the U.S. population
45–74 years of age. Diabetes Care. 2005;28(2):307–11.
4. Lin KW, Chang C. Screening for type 2 diabetes mellitus in adults. Am Fam
Physician. 2009;80(10):1141.
5. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict
type 2 diabetes risk. Diabetes Care. 2003;26(3):725–31.
6. Gray LJ, Taub NA, Khunti K, Gardiner E, Hiles S, Webb DR, Srinivasan BT,
Davies MJ. The Leicester Risk Assessment score for detecting undiagnosed
Type 2 diabetes and impaired glucose regulation for use in a multiethnic
UK setting. Diabet Med. 2010;27(8):887–95.
7. NICE. Preventing type 2 diabetes: risk identification and interventions for
individuals at high risk. 2012.
8. Chamnan P, Simmons RK, Forouhi NG, Luben RN, Khaw KT, Wareham NJ,
Griffin SJ. Incidence of type 2 diabetes using proposed HbA1c diagnostic
criteria in the european prospective investigation of cancer-norfolk cohort:
implications for preventive strategies. Diabetes Care. 2011;34(4):950–6.
9. Ebell M, Herzstein J. Improving quality by doing less: overscreening. Am
Fam Physician. 2015;91(1):22–4.
10. Siu AL. US Preventive Services Task Force. Screening for Abnormal Blood
Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force
Recommendation Statement. Ann Intern Med. 2015;163(11):861–8.
Table 3 Signal and noise of HbA1c, time when signal > noise













30–44 BMI Underweight 0.02 0.18 10.5
Normal 0.03 0.18 6.7
Overweight 0.05 0.22 4.5
Obese 0.13 0.30 2.4
Framingham
Risk Score
0–10% 0.03 0.19 6.1
10–20% 0.11 0.23 2.1
Over 20% 0.10 0.20 2.0
45–59 BMI Underweight 0.02 0.18 10.4
Normal 0.03 0.18 6.3
Overweight 0.05 0.22 4.5
obese 0.08 0.31 4.1
Framingham
Risk Score
0–10% 0.03 0.18 6.0
10–20% 0.04 0.21 5.5
Over 20% 0.06 0.25 4.1
60–74 BMI Underweight 0.03 0.17 6.6
Normal 0.03 0.18 7.2
overweight 0.04 0.21 5.0
Obese 0.06 0.23 3.9
Framingham
Risk Score
0–10% 0.02 0.17 8.0
10–20% 0.03 0.19 6.7
Over 20% 0.04 0.21 5.3
aSignal defined as variance of random slope; noise defined as variance of
residual between model-generated and observed HbA1c. Values represent
square root of above measures to obtain HbA1c as %
Table 4 DM screening intervals for HbA1c screening test by
DM score (years)
Age 30–44 Age 45–59 Age 60–74
High DM riska 4.8 5.4 5.5
Low DM risk 8.2 7.2 7.3
aRisk score calculated based on Nanri et al. [28]; cut-off point modified from
10 to 9 due to omission of waist circumference
Ohde et al. BMC Endocrine Disorders  (2016) 16:65 Page 9 of 10
11. McDonald TJ, Warren R. Diagnostic confusion? Repeat HbA1c for the diagnosis
of diabetes. Diabetes Care. 2014;37(6):e135–6.
12. American Diabetes Association. Screening for diabetes. Diabetes Care.
2002;25 Suppl 1:S21–4.
13. Centers for Disease Control and Prevention. National diabetes statistics
report: estimates of diabetes and its burden in the United States, 2014.
Atlanta: US Department of Health and Human Services; 2014.
14. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS.
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.
JAMA. 2003;289(1):76–9.
15. Kahn R, Alperin P, Eddy D, Borch-Johnsen K, Buse J, Feigelman J, Gregg E,
Holman RR, Kirkman MS, Stern M, Tuomilehto J, Wareham NJ. Age at initiation
and frequency of screening to detect type 2 diabetes: a cost-effectiveness
analysis. Lancet. 2010;375(9723):1365–74.
16. Takahashi O, Farmer AJ, Shimbo T, Fukui T, Glasziou PP. A1C to detect
diabetes in healthy adults: when should we recheck? Diabetes Care. 2010;
33(9):2016–7.
17. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM,
Kannel WB. General cardiovascular risk profile for use in primary care the
Framingham Heart Study. Circulation. 2008;117(6):743–53.
18. Kuusisto J, Laakso M. Update on type 2 diabetes as a cardiovascular disease
risk equivalent. Curr Cardiol Rep. 2013;15:1–6.
19. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE.
Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2
diabetes. Diabetes Care. 2002;25(7):1129–34.
20. WHO Expert Consultation. Appropriate body-mass index for Asian
populations and its implications for policy and intervention strategies.
Lancet. 2004;363(9403):157–63.
21. Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria
and classification of obesity in Japan and Asia‐Oceania. Asia Pac J Clin
Nutr. 2002;11(s8):S732–7.
22. Bell KJ, Hayen A, Irwig L, Takahashi O, Ohde S, Glasziou P. When to
remeasure cardiovascular risk in untreated people at low and intermediate
risk: observational study. BMJ. 2013;346:f1895.
23. Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB,
Pasternak RC, Smith Jr SC, Stone NJ, Coordinating Committee of the
National Cholesterol Education P. Implications of recent clinical trials for the
National Cholesterol Education Program Adult Treatment Panel III
Guidelines. J Am Coll Cardiol. 2004;44(3):720–32.
24. Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama
A, Kokubo Y, Okayama A, Miyamoto Y. Predicting coronary heart disease
using risk factor categories for a Japanese urban population, and
comparison with the framingham risk score: the suita study. J Atheroscler
Thromb. 2014;21(8):784–98.
25. Stevens RJ, Oke J, Perera R. Statistical models for the control phase of
clinical monitoring. Stat Methods Med Res. 2010;19(4):394–414.
26. Perera R, McFadden E, McLellan J, Lung T, Clarke P, Perez T, Fanshawe T,
Dalton A, Farmer A, Glasziou P, et al. Optimal strategies for monitoring lipid
levels in patients at risk or with cardiovascular disease: a systematic review
with statistical and cost-effectiveness modelling. Health Technol Assess.
2015;19(100):1–402.
27. Glasziou PP, Irwig L, Heritier S, Simes RJ, Tonkin A, Investigators LS.
Monitoring cholesterol levels: measurement error or true change? Ann
Intern Med. 2008;148(9):656–61.
28. Nanri A, Nakagawa T, Kuwahara K, et al. Development of risk score for
predicting 3-year incidence of Type 2 diabetes: Japan Epidemiology
Collaboration on Occupational Health Study. PLoS One. 2015;10(11):
e0142779.
29. Simmons RK, Rahman M, Jakes RW, Yuyun MF, Niggebrugge AR, Hennings
SH, Williams DR, Wareham NJ, Griffin SJ. Effect of population screening for
type 2 diabetes on mortality: long-term follow-up of the Ely cohort.
Diabetologia. 2011;54(2):312–9.
30. Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, Sargeant LA, Williams KM,
Prevost AT, Kinmonth AL, Wareham NJ, Griffin SJ. Screening for type 2
diabetes and population mortality over 10 years (ADDITION-Cambridge):
a cluster-randomised controlled trial. Lancet. 2012;380(9855):1741–8.
31. Selph S, Dana T, Blazina I, Bougatsos C, Patel H, Chou R. Screening for type
2 diabetes mellitus: a systematic review for the U.S. Preventive Services Task
Force. Ann Intern Med. 2015;162(11):765–76.
32. Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among
adults and youth: United States, 2011–2014. NCHS Data Brief. 2015;219:1–8.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ohde et al. BMC Endocrine Disorders  (2016) 16:65 Page 10 of 10
